Obesity medication lorcaserin activates brainstem GLP-1 neurons to reduce food intake and augments GLP-1 receptor agonist induced appetite suppression

OBJECTIVE: Overweight and obesity are endemic in developed countries, with a substantial negative impact on human health. Medications developed to treat obesity include agonists for the G-protein coupled receptors glucagon-like peptide-1 (GLP-1R; e.g. liraglutide), serotonin 2C (5-HT(2C)R; e.g, lorc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Stefan, Brierley, Daniel I., Leeson-Payne, Alasdair, Jiang, Wanqing, Chianese, Raffaella, Lam, Brian Y.H., Dowsett, Georgina K.C., Cristiano, Claudia, Lyons, David, Reimann, Frank, Gribble, Fiona M., Martinez de Morentin, Pablo B., Yeo, Giles S.H., Trapp, Stefan, Heisler, Lora K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841057/
https://www.ncbi.nlm.nih.gov/pubmed/36592795
http://dx.doi.org/10.1016/j.molmet.2022.101665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841057/
https://www.ncbi.nlm.nih.gov/pubmed/36592795
http://dx.doi.org/10.1016/j.molmet.2022.101665

Ejemplares similares